Idorsia initiates a multiple-dose efficacy and safety study

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
18
Idorsia initiates a multiple-dose efficacy and safety study with cenerimod for the treatment of systemic lupus erythematosus

Allschwil, Switzerland - January 7, 2019 Idorsia Ltd (SIX: IDIA) today announced that the first patient has been enrolled into a multiple-dose study to evaluate the efficacy and safety of cenerimod, a selective S1P 1 receptor modulator for the treatment of adults with systemic lupus erythematosus (SLE).

Idorsia is investigating cenerimod, an oral once-daily tablet in patients with lupus. Cenerimod has the potential to add a distinct mechanism to the treatment armamentarium for this underserved patient population.

Martine Clozel, MD and Chief Scientific Officer, commented: "Cenerimod was selected for development due to its unique properties in experimental models. We believe that a combination of high selectivity for the S1P 1 receptor and an attenuated calcium response in endothelial cells are responsible for the excellent preclinical efficacy without bronchoconstrictor or vasoconstrictor side-effects. SLE was selected as the target indication because of the pathogenic role of T and B lymphocytes and antibody production in this disease."

In the Phase 1 program, cenerimod showed marked and sustained circulating lymphocyte lowering effects. A Phase 2 safety study with cenerimod, which investigated the pharmacodynamics, safety and tolerability of cenerimod in adult patients with SLE, has been conducted. The study enrolled 67 patients to receive either 0.5, 1, 2 or 4 mg/day of cenerimod or placebo over a treatment period of 12 weeks. The results of the study showed that cenerimod induces a dose-dependent, sustained reduction in circulating lymphocyte counts that was reversible after treatment discontinuation. Cenerimod was well tolerated at all dose levels. The occurrence of adverse events was similar in all five treatment groups.

About the study Cenerimod is being investigated in a multiple-dose study to evaluate its efficacy and safety for the treatment of adult patients with moderately to severely active, autoantibody-positive SLE. The multicenter, randomized, double-blind, placebo-controlled, parallel-group study will enroll around 500 patients, who will be randomized into four cenerimod treatment arms: 0.5, 1, 2, and 4mg once-daily orally or placebo for up to 12 months. Patients will receive study treatment in addition to background SLE therapy. The study aims to validate the appropriate dose, patient population and endpoints for further development in SLE.

Guy Braunstein, MD and Head of Global Clinical Development, commented:

"This study is based on a clinical pharmacology program in healthy volunteers and a Phase 2 safety study in patients with lupus, which showed that cenerimod reduced circulating lymphocytes in a dose-dependent manner and was safe and well tolerated at doses up to 4 mg. It has been designed to include input from health authorities. As background therapy may confound the treatment effect, the protocol recommends keeping SLE medications as stable as possible during the double-blind treatment period. The study also considers important patient perspectives, such as the overall quality of life and debilitating symptoms like fatigue."

Notes to the editor

About systemic lupus erythematosus SLE - known more simply as "lupus" since it is the most common form of lupus - is an autoimmune disease, which means that the body's immune system malfunctions and attacks the body's own tissues, causing inflammation and organ damage. Some autoimmune diseases affect individual organs, but in the case of lupus, most parts of the body can be affected: most commonly the skin, joints, gut, blood cells, and lungs, as well as the brain, heart, and kidneys.

Lupus can range from mild to life-threatening and can randomly become worse (so-called 'flare ups') and then better again, which can make living with lupus unpredictable and its impact on day-to-day life wide-ranging. Around five million people worldwide have a form of lupus and while it affects people of all races, genders, and ages, as much as ninety percent of diagnosed cases are in women. The condition is also more common in people of Afro-Caribbean and Asian origin compared to Caucasians and is likely to affect these ethnic groups more severely.

There is no cure for lupus. Most people with lupus are prescribed a combination of different medications including anti-inflammatory, anti-malarial drugs, corticosteroids, immunomodulators.

About cenerimod in systemic lupus erythematosus How and why lupus affects the immune system's defense mechanisms is still not fully understood. However, T and B lymphocytes are considered the key immune system cells that contribute to the symptoms of the disease, because their normal development and mechanism for developing tolerance to the body's own tissues has malfunctioned in lupus.

T and B lymphocytes have receptors on the surface called "Sphingosine-1-phosphate receptor 1" (S1P 1 ). This receptor senses the gradient of sphingosine-1-phosphate or S1P, which is high in blood, guiding the lymphocytes out of lymph nodes towards the circulation.

Cenerimod, a selective S1P 1 receptor modulator, binds to the S1P 1 receptor on the surface of T and B lymphocytes. This interaction leads to internalization of the S1P 1 receptor, so that the lymphocyte can no longer sense S1P. As a result, the lymphocytes are held in the lymph nodes, reducing the availability of these key players in inflammation to the affected organs and tissues. The effect of cenerimod on lymphocyte trafficking is reflected by the dose-dependent, sustained and reversible reduction in circulating lymphocyte counts observed upon administration of cenerimod.

Key scientific literature 1.        Piali L, et al. Pharmacol Res Perspect. 2017 Dec;5(6). 2.        Borchers AT, et al. Autoimmun Rev. 2010; 9(5):A277-87. 3.        Pons-Estel GJ, et al. Semin Arthritis Rheum. 2010; 39(4):257-68. 4.        Govoni M, et al. Lupus. 2006; 15:110-113. 5.        Rahman A, Isenberg DA. N Engl J Med. 2008; 358:929-39. 6.        Abu-Shakra M, et al. J Rheumatol 1995; 22(7):1259-64.

About Idorsia Idorsia Ltd is reaching out for more - We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe's leading biopharmaceutical companies, with a strong scientific core.

Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet - the ideal constellation to bringing R&D efforts to business success.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 700 highly qualified specialists dedicated to realizing our ambitious targets.

For further information, please contact Andrew C. Weiss Senior Vice President, Head of Investor Relations & Corporate Communications Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil +41 (0) 58 844 10 10 www.idorsia.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 125

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 114

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 73

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 122

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Atalanta Takes Formal Verification Into Critical Systems

Updated Category News Views 515

A week of bewildering infrastructure failures is a nasty time to discover nobody can explain the machinery. That was the backdrop for Atalanta CEO and co-founder Anjana Rajan at the National Academies of Sciences, Engineering, and Medicine's Cyber Resilience Forum, which concluded November 20 after two days in Washington. Her central point deserves more attention than the...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 158

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 65

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading

Top 5 Most Recently Viewed Articles

The Hiring Crisis for Gen Z: Understanding Key Economic Factors

Updated Category News Views 472

The Hiring Crisis for Gen Z In today's economy, young Americans, particularly those under 25, are experiencing a significant challenge in securing employment. This issue, marked by increasing unemployment rates among recent graduates, is creating alarm. Most agree that the factors influencing this crisis point to a stagnation in hiring practices rather than advancements...

Continue Reading
Recent Class Action Highlights Concerns Around Bumble Inc. Shares

Updated Category News Views 78

Understanding the Recent Class Action Against Bumble Inc. The landscape of online dating and social networking continues to evolve, with Bumble Inc. playing a significant role in shaping user experiences. Recently, a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Bumble Inc. (BMBL). This...

Continue Reading
Analyzing Li Auto Inc's Market Sentiment and Short Interest

Updated Category News Views 165

Understanding Market Sentiment for Li Auto Inc Li Auto Inc (NYSE: LI) has recently witnessed a noteworthy shift in its short interest percentage. As reported, the company’s short interest has decreased by 13.66%, with approximately 20.65 million shares being sold short. This figure represents about 5.12% of the total shares that are available for trading. The data...

Continue Reading
Equity Markets Take a Breather During Holiday Pause

Updated Category News Views 245

Markets Hold Steady as Investors Reflect With the US markets taking a break for the Thanksgiving holiday, global equities have collectively paused for a moment of reflection. This calmness among investors is primarily influenced by current expectations regarding a dovish shift in Federal Reserve policy. Speculation is high, with many assigning about an 80% probability for...

Continue Reading
University of Phoenix's New Leadership in Counseling: What’s Next?

Updated Category News Views 358

New Leadership Spotlight: Yurandol Thompson Elevated The University of Phoenix has gone and done it again, appointing Yurandol Thompson as Associate Dean for Counseling, effective January 29, 2026. Now, this isn’t just any old shake-up. Dr. Thompson brings over a decade of experience in clinical operations and programmatic excellence. I mean, come on—sounds impressive...

Continue Reading